You are here
Testosterone Therapy Not Linked to Increased Prostate Cancer Risk
The University of Texas Medical Branch at Galveston used SEER–Medicare-linked data to identify 52,570 men who were diagnosed with prostate cancer between January 2001 and December 2006 and who had a minimum of five years of continuous enrollment in Medicare before their cancer diagnosis. In the five years before diagnosis, 574 men had a history of testosterone use.
The study, which was published in the Journal of Urology, analyzed the data based on diagnosis codes for both outpatient and hospitalization services as well as on physician claims. The study results demonstrated that exposure to testosterone therapy was not associated with an increased risk of aggressive prostate cancer or with an increased risk of high-grade prostate cancer.
Although several longitudinal studies have shown no increased risk of prostate cancer incidence with testosterone use, no population-based studies have examined the association of high-grade prostate cancer with testosterone exposure beyond one year.
Given the slow growth of prostate cancer, the new report offers important information for physicians, patients, and the general public, according to lead author Dr. Jacques Baillargeon. "This study's findings offer important information regarding the risk-benefit assessment for men with testosterone deficiency who are considering treatment," he said.
Source: Medical Xpress, October 5, 2015